Sensei Biotherapeutics, Inc. Common Stock (SNSE)
Sensei Biotherapeutics, Inc. (SNSE) is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies. The company specializes in designing vaccine and antibody-based treatments to target underlying mechanisms of cancer and improve immune response. Its proprietary platform aims to address unmet needs in cancer care through personalized and novel immunotherapies.
Company News
Sensei Biotherapeutics announced promising Phase 1/2 trial results for solnerstotug, a monoclonal antibody targeting VISTA, showing 50% 6-month progression-free survival in PD-(L)1 resistant tumors at the 15 mg/kg dose, with plans to advance to Phase 2 studies in Non-Small Cell Lung Cancer and Merkel Cell Carcinoma.
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares surged 358% to $134.37 in pre-market trading after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge Capital Acquisition Corp. Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) shares rose 25.8% to $0.8686 in pre-market trading. Sensei...
Insiders are scooping up these penny stocks in February. The post Best Penny Stocks To Buy? 3 To Watch With Insider Buying In February appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Stanley Druckenmiller’s 13F portfolio value decreased from $3.89B to $3.48B this quarter. The top three positions are at ~29% of the portfolio.
Sensei Biotherapeutics, Inc. (SNSE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.